ScPhar­ma's stock droops on 'd­e­fi­cien­cies' as FDA toss­es back heart fail­ure drug ap­pli­ca­tion

It’s vague news from the FDA Thurs­day morn­ing that halt­ed — then tanked — the stock of scPhar­ma­ceu­ti­cals, a Burling­ton, MA-based com­pa­ny await­ing a reg­u­la­to­ry de­ci­sion on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER